KalVista Pharmaceuticals, Inc.
KALV
$19.56
-$1.30-6.23%
NASDAQ
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Yield Index
Headlines
4/16/2026
-
MarketBeat
4/16/2026
-
Yahoo! Finance: News
4/16/2026
-
MarketBeat
Analysts Are Bullish on Top Healthcare Stocks: Guardant Health (GH), KalVista Pharmaceuticals (KALV)
4/16/2026
-
TipRanks Financial Blog
4/13/2026
-
Simply Wall St
4/13/2026
-
MarketBeat
4/8/2026
-
MarketBeat
4/8/2026
-
Business Wire
4/7/2026
-
SeekingAlpha
4/7/2026
-
Seeking Alpha - Healthcare
4/7/2026
-
Seeking Alpha - Long Ideas
4/7/2026
-
Ticker Report
4/5/2026
-
MarketBeat
4/3/2026
-
Simply Wall St
4/2/2026
-
Business Wire
4/2/2026
-
Simply Wall St
4/2/2026
-
Simply Wall St
4/2/2026
-
MarketBeat
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Receives Average Rating of "Moderate Buy" from Analysts
4/1/2026
-
MarketBeat
3/31/2026
-
MarketBeat
3/31/2026
-
Tickeron - Stocks
3/30/2026
-
Business Wire
3/30/2026
-
MarketBeat
3/29/2026
-
TipRanks Financial Blog
3/29/2026
-
TipRanks Financial Blog
Income Statement
Total Revenue (TTM)
EBITDA (TTM)
EBIT (TTM)
Net Income (TTM)
Balance Sheet
Total Assets (Q)
Total Debt (Q)
Total Liabilities (Q)
Book Value Per Share (Q)
Cash Flow
Cash from Operations (TTM)
Cash from Investing (TTM)
Cash from Financing (TTM)
Net Change in Cash (TTM)
Filings
Filing Date
Wednesday, March 25, 2026
Period Date
Wednesday, December 31, 2025
Next Filing
Week of Sep 7 and 11 (est)
Price History
Beta
7-Day Total Return
30-Day Total Return
60-Day Total Return
90-Day Total Return
Year to Date Total Return
1-Year Total Return
2-Year Total Return
3-Year Total Return
5-Year Total Return
52-week Low
52-week High
Valuation
Enterprise Value
Price/Sales (TTM)
Price/Book (Q)
Dividends and Shares
Shares Outstanding
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
Phone Number
857 999 0075
Address
200 Crossing Boulevard
Framingham, MA 01702
Framingham, MA 01702
Country
Year Founded
--
Business Description
Sector
KalVista Pharmaceuticals, Inc., a biopharmaceutical company, develops oral therapies for individuals for rare diseases with unmet needs. Its lead product candidate is EKTERLY, a fast-acting...
more